Correlates and Consequences of an Acute Change in eGFR in Response to the SGLT2 Inhibitor Dapagliflozin in Patients with CKD

Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial

(2020) David Z I Cherney et al.   Lancet Diabetes & Endocrinology

Dapagliflozin in Patients with Chronic Kidney Disease

(2020) Hiddo J.L. Heerspink et al.   NEW ENGLAND JOURNAL OF MEDICINE

Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice.

(2020) Megumi Oshima et al.   KIDNEY INTERNATIONAL

Characterization and implications of the initial estimated glomerular filtration rate ‘dip’ upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial

(2020) Bettina J. Kraus et al.   KIDNEY INTERNATIONAL

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

(2019) Vlado Perkovic et al.   NEW ENGLAND JOURNAL OF MEDICINE

Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial

(2019) Carol Pollock et al.   Lancet Diabetes & Endocrinology

SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis

(2019) Brendon L Neuen et al.   Lancet Diabetes & Endocrinology

Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial

(2019) Ofri Mosenzon et al.   Lancet Diabetes & Endocrinology

The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial

(2019) Erik J.M. van Bommel et al.   KIDNEY INTERNATIONAL

Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial

(2019) Hiddo J L Heerspink et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials

(2018) Vlado Perkovic et al.   Lancet Diabetes & Endocrinology

Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial

(2018) Christoph Wanner et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus

(2016) Hiddo J.L. Heerspink et al.   CIRCULATION

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

(2016) Christoph Wanner et al.   NEW ENGLAND JOURNAL OF MEDICINE

An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function

(2011) Frank A. Holtkamp et al.   KIDNEY INTERNATIONAL